Enosium Life Science strengthens strategic offering with the acquisition of Rweality
Rweality to bolster Enosium Life Science’s strategic market access and healthcare products value services
Paris, April 1st, 2025 – Enosium Life Science, a group specializing in life sciences, today announces the acquisition of Rweality, a consulting and service firm expert in the evaluation of public policies, technologies, and healthcare practices.
This strategic move marks a key milestone in Enosium Life Science's growth and ambition to build a multi-specialist group across the entire value chain of healthcare products, from clinical development to scientific communication.
Rweality brings a wide range of expertise in Real-World Evidence (RWE) and health technology impact assessment to address the critical needs of its clients: market access and pricing strategy, data generation strategies, health system analysis and efficiency, patient journey evaluation, and actual access to hospitals.
This strategic acquisition strengthens Enosium Life Science’s capabilities in market access and data valuation for healthcare products. The experts from Rweality will reinforce and complement Enosium's existing team of specialists in European market access, medical communication, and Health Economics and Outcomes Research (HEOR).
A Shared Vision and Strong Synergies
Antoine Amer, founder and CEO of Enosium Life Science, stated: "I am very pleased to welcome Sandrine Bourguignon, a recognized leader and expert in the public health and health economics ecosystem, and the entire Rweality team to our group. This combination aligns perfectly with our development strategy and will accelerate our growth and leadership in market access services in France and Europe."
Sandrine Bourguignon, founder and CEO of Rweality, added: "Joining Enosium Life Science is a fantastic opportunity for Rweality. Our complementary expertise and shared market vision will enable us to accelerate the value demonstration of our clients' healthcare products."
About Enosium Life Science
Founded in January 2024 by Dr. Antoine Amer with financial support from Otium, Enosium Life Science is an integrated group of scientific services (clinical research, regulatory affairs, market access and medico-economic valuation, medical affairs, marketing, and public affairs) for the healthcare industry in Europe. Its mission is to unite the best expertise across Europe to offer a unique and complete range of scientific services, supporting innovation and excellence in life sciences and enabling broader and faster access for European patients to medical innovations. For more information: www.enosium.com
About Rweality
Rweality is a firm specializing in studies, consulting, and services related to the use of real-world data, Health Economics and Outcomes Research (HEOR), and evaluations of health technologies and policies for product and business strategies. The expertise of the Rweality teams addresses key needs, including market access and pricing, health system analysis, patient pathway qualification, and the creation of innovative solutions to support field access.
PR contact Enosium: Florence Portejoie, fportejoie@fp2com.fr
Contact Rweality: info@rweality.com
PR contact Otium: Image Sept, otium@image7.fr
